|Podcasts|September 16, 2021
Episode 91: A New Way to Partner With Academia
Author(s)Elaine Quilici, Miranda Schmalfuhs
Dr. Michael Henderson, chief business officer of BridgeBio Pharma, and one of Pharm Exec’s 2021 Emerging Pharma Leaders, discusses how his company goes beyond the traditional “hand off” approach between academia and industry, and looks to partner with institutions early on to fill important voids in drug development.
Advertisement
Dr. Michael Henderson, Chief Business Officer of BridgeBio Pharma, talks about how his company is partnering with academia in a novel way to develop important programs that might otherwise be dropped.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors
2
Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil
3
How are the Drug Pricing Negotiations Impacting Pharma's Relationship with DC?
4
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
5
